TY - JOUR
T1 - SRCircumventing imatinib resistance
AU - Deininger, Michael W.N.
AU - Druker, Brian J.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004/8
Y1 - 2004/8
N2 - The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.
AB - The ABL inhibitor imatinib is a highly effective therapy for patients with chronic myeloid leukemia. Relapses after an initial response have been observed in some patients, and mutations of the BCR-ABL gene are the most common mechanism driving these relapses. Alternative ABL inhibitors have been identified that inhibit most of the common BCR-ABL mutations, and one has entered clinical trials. The structural basis for these results has yielded significant insights into the mechanism of action of these compounds, mechanisms of resistance, and their ability to inhibit the BCR-ABL mutants. These studies demonstrate the importance and impact of conducting scientific studies as part of clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=5144231866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5144231866&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2004.08.006
DO - 10.1016/j.ccr.2004.08.006
M3 - Review article
C2 - 15324693
AN - SCOPUS:5144231866
SN - 1535-6108
VL - 6
SP - 108
EP - 110
JO - Cancer Cell
JF - Cancer Cell
IS - 2
ER -